Squarepoint’s Roivant Sciences ROIV Stock Holding History

Squarepoint’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.8M	Buy	+475,571	New	+$14.1M	0.02%	783
2026 Q1	–	Sell	-516,955	Closed	-$11.2M	–	4861
2025 Q4	$11.2M	Sell	516,955 -916,074	-64%	-$18.1M	0.01%	1024
2025 Q3	$21.7M	Sell	1,433,029 -778,646	-35%	-$9.64M	0.02%	700
2025 Q2	$24.9M	Buy	2,211,675 +2,129,150	+2,580%	+$23.1M	0.03%	662
2025 Q1	$833K	Buy	+82,525	New	+$892K	﹤0.01%	2832
2024 Q3	–	Sell	-47,579	Closed	-$503K	–	4613
2024 Q2	$503K	Buy	47,579 +6,091	+15%	+$66.7K	﹤0.01%	3081
2024 Q1	$437K	Sell	41,488 -71,338	-63%	-$769K	﹤0.01%	3138
2023 Q4	$1.27M	Buy	112,826 +25,237	+29%	+$246K	﹤0.01%	2355
2023 Q3	$1.02M	Buy	+87,589	New	+$990K	﹤0.01%	2299
2023 Q2	–	Sell	-54,174	Closed	-$400K	–	3934
2023 Q1	$400K	Sell	54,174 -17,112	-24%	-$141K	﹤0.01%	2420
2022 Q4	$570K	Buy	71,286 +46,646	+189%	+$259K	﹤0.01%	2197
2022 Q3	$79K	Sell	24,640 -2,076	-8%	-$8.04K	﹤0.01%	2821
2022 Q2	$109K	Sell	26,716 -89,209	-77%	-$354K	﹤0.01%	2605
2022 Q1	$573K	Buy	+115,925	New	+$765K	﹤0.01%	1929

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Squarepoint's ROIV Position: Q2 2026 in Review

Squarepoint opened a new position in Roivant Sciences (ROIV) in Q2 2026: 475,571 shares worth $16.8M. The stake represents 0.02% of the portfolio and ranks #783 among its holdings. This is a return to the name: Squarepoint previously reported a position in ROIV as recently as Q4 2025.

Squarepoint first reported a position in ROIV in Q1 2022 and has held it in 14 quarters since. The position peaked at $24.9M in Q2 2025. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Squarepoint held 475,571 shares of Roivant Sciences worth $16.8M as of Q2 2026.
Roivant Sciences was a new Squarepoint position in Q2 2026.
Roivant Sciences made up 0.02% of Squarepoint's portfolio in Q2 2026, its #783 holding.
Squarepoint first reported a position in Roivant Sciences in Q1 2022 and has held it in 14 quarters since.
Squarepoint's Roivant Sciences position peaked at $24.9M in Q2 2025.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.